{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:45:26Z","timestamp":1793371526714,"version":"4.5.0"},"reference-count":18,"publisher":"Georg Thieme Verlag KG","issue":"02","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":130,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sleep Sci"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A 24-year-old woman with treatment-resistant depressive symptoms and chronic insomnia developed acute, intrusive suicidal ideation with intent on day 5 after starting lemborexant 10\u2009mg nightly. Emergency assessment did not identify intoxication, metabolic disturbance, psychosis, mania, akathisia, or other acute precipitants. Pretreatment polysomnography showed severe insomnia with a sleep efficiency of 14.5% and absent REM sleep, without sleep-disordered breathing. Lemborexant was discontinued immediately, and suicidal ideation resolved completely within 24\u2009hours without additional pharmacological intervention. The Naranjo Adverse Drug Reaction Probability Scale yielded a score of 6, consistent with a probable adverse drug reaction. At 6-month follow-up, the patient remained free of suicidal ideation with sustained functional stability. This case adds clinically relevant documentation to pharmacovigilance concerns about potential suicidality with dual orexin receptor antagonists and supports structured suicide risk assessment and early follow-up when initiating these agents in patients with mood disorders.<\/jats:p>","DOI":"10.1055\/s-0046-1829078","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:47:12Z","timestamp":1791589632000},"page":"001-005","source":"Crossref","is-referenced-by-count":1,"title":["Acute Onset of Suicidal Ideation after Starting Lemborexant in a Patient with a Mood Disorder"],"prefix":"10.1055","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3194-320X","authenticated-orcid":false,"given":"Renato Rodrigo","family":"Silva","sequence":"additional","affiliation":[{"name":"Private practice, Uberl\u00e2ndia, Minas Gerais, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8436-6154","authenticated-orcid":false,"given":"Marjorie Mastellaro","family":"Baruzzi","sequence":"additional","affiliation":[{"name":"Program for Education, Research, and Care in Treatment-Resistant Depression, Self-Injury, and Suicidality, Hospital das Cl\u00ednicas, Faculty of Medicine, University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8639-4746","authenticated-orcid":false,"given":"Bianca Besteti Fernandes","family":"Damiano","sequence":"additional","affiliation":[{"name":"Program for Education, Research, and Care in Treatment-Resistant Depression, Self-Injury, and Suicidality, Hospital das Cl\u00ednicas, Faculty of Medicine, University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3180-7926","authenticated-orcid":false,"given":"Rodolfo Furlan","family":"Damiano","sequence":"additional","affiliation":[{"name":"Program for Education, Research, and Care in Treatment-Resistant Depression, Self-Injury, and Suicidality, Hospital das Cl\u00ednicas, Faculty of Medicine, University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"},{"name":"Department and Institute of Psychiatry, Hospital das Cl\u00ednicas, Faculty of Medicine, University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"13888","DOI":"10.1038\/s41598-020-70866-6","article-title":"Sleep disturbances as risk factors for suicidal thoughts and behaviours: a meta-analysis of longitudinal studies","volume":"10","author":"L M Harris","year":"2020","journal-title":"Sci Rep"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/cpdd.817","article-title":"Pharmacokinetics, pharmacodynamics and safety of the dual orexin receptor antagonist lemborexant: findings from single-dose and multiple-ascending-dose phase 1 studies in healthy adults","volume":"10","author":"I Landry","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"e1918254","DOI":"10.1001\/jamanetworkopen.2019.18254","article-title":"Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomised clinical trial","volume":"2","author":"R Rosenberg","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"09","key":"ref5","doi-asserted-by":"crossref","first-page":"zsaa123","DOI":"10.1093\/sleep\/zsaa123","article-title":"Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2","volume":"43","author":"M K\u00e4rpp\u00e4","year":"2020","journal-title":"Sleep"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.sleep.2021.01.048","article-title":"Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial","volume":"80","author":"J Yardley","year":"2021","journal-title":"Sleep Med"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40263-025-01245-w","article-title":"A 12-week, open-label, multicenter pilot study to evaluate the efficacy and safety of lemborexant in patients with insomnia comorbid with depressive episodes (SELENADE)","volume":"40","author":"Y Takaesu","year":"2026","journal-title":"CNS Drugs"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/1752-1947-7-223","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"7","author":"J J Gagnier","year":"2013","journal-title":"J Med Case Rep"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"C A Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"06","key":"ref10","doi-asserted-by":"publisher","first-page":"23br14923","DOI":"10.4088\/JCP.23br14923","article-title":"Dual orexin receptor antagonists and suicide risk: findings from the WHO spontaneous reporting database","volume":"84","author":"F Salvo","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1436405","DOI":"10.3389\/fphar.2024.1436405","article-title":"Data mining and safety analysis of dual orexin receptor antagonists (DORAs): a real-world pharmacovigilance study based on the FAERS database","volume":"15","author":"M Jiang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"06","key":"ref12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/14740338.2024.2361300","article-title":"Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"24","author":"R S McIntyre","year":"2025","journal-title":"Expert Opin Drug Saf"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1124\/dmd.120.000229","article-title":"Disposition and metabolism of [14C]lemborexant in healthy human subjects and characterisation of its circulating metabolites","volume":"49","author":"T Ueno","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"23","key":"ref14","doi-asserted-by":"crossref","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","article-title":"Neurons containing hypocretin (orexin) project to multiple neuronal systems","volume":"18","author":"C Peyron","year":"1998","journal-title":"J Neurosci"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev.neuro.25.112701.142826","article-title":"The role of hypocretins (orexins) in sleep regulation and narcolepsy","volume":"25","author":"S Taheri","year":"2002","journal-title":"Annu Rev Neurosci"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.yfrne.2018.06.003","article-title":"Orexins and stress","volume":"51","author":"L A Grafe","year":"2018","journal-title":"Front Neuroendocrinol"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41398-020-00995-z","article-title":"Prefrontal activation in suicide attempters during decision making with emotional feedback","volume":"10","author":"A Alacreu-Crespo","year":"2020","journal-title":"Transl Psychiatry"},{"issue":"06","key":"ref18","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41386-020-0632-0","article-title":"Ventromedial prefrontal value signals and functional connectivity during decision-making in suicidal behavior and impulsivity","volume":"45","author":"V M Brown","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"04","key":"ref19","doi-asserted-by":"publisher","first-page":"pyag009","DOI":"10.1093\/ijnp\/pyag009","article-title":"Safety, tolerability, and preliminary efficacy of seltorexant versus quetiapine extended release as adjunctive therapy in major depressive disorder: a randomized, flexible-dose, 6-month, parallel-group, exploratory study","volume":"29","author":"C Pinter","year":"2026","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["Sleep Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0046-1829078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:48:09Z","timestamp":1791589689000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0046-1829078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":18,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2026,7,17]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["s00461829078"],"URL":"https:\/\/doi.org\/10.1055\/s-0046-1829078","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1984-0659","1984-0063"],"issn-type":[{"value":"1984-0659","type":"print"},{"value":"1984-0063","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}